Updating results

18 results

Sort: Relevance | Date

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points

Key therapeutic topic Published March 2019 Last updated September 2019

Shared decision making (KTT23)

KTT23 Shared decision making Key points In the context of medicines optimisation, shared

Key therapeutic topic Published March 2019 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE

Key therapeutic topic Published January 2015 Last updated September 2019

Biosimilar medicines (KTT15)

KTT15 Biosimilar medicines Options for local implementation Biosimilar medicines have

Key therapeutic topic Published February 2016 Last updated February 2018

Multimorbidity and polypharmacy (KTT18)

KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with

Key therapeutic topic Published January 2017 Last updated September 2019

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Lipid-modifying drugs (KTT3)

KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

KTT7 Antipsychotics in people living with dementia Key points The risks and limited

Key therapeutic topic Published January 2015 Last updated September 2019

Wound care products (KTT14)

KTT14 Wound care products Key points A large number of wound dressings are available

Key therapeutic topic Published January 2015 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Hypnotics (KTT6)

KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)

Key therapeutic topic Published January 2015 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can

Key therapeutic topic Published January 2017 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points

Key therapeutic topic Published January 2017 Last updated September 2019

Non-steroidal anti-inflammatory drugs (KTT13)

KTT13 Non-steroidal anti-inflammatory drugs Options for local implementation Review

Key therapeutic topic Published January 2015 Last updated February 2018

Safer insulin prescribing (KTT20)

KTT20 Safer insulin prescribing Key points Several new insulin products have been launched

Key therapeutic topic Published January 2017 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation

Key therapeutic topic Published February 2018 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are

Key therapeutic topic Published January 2015 Last updated September 2019

Antimicrobial stewardship: prescribing antibiotics (KTT9)

KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance

Key therapeutic topic Published January 2015 Last updated September 2019